Polycystic Ovarian Syndrome - Pipeline Review, H2 2017

Publisher Name :
Date: 29-Aug-2017
No. of pages: 54
Inquire Before Buying

Polycystic Ovarian Syndrome - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Polycystic Ovarian Syndrome - Pipeline Review, H2 2017, provides an overview of the Polycystic Ovarian Syndrome (Women's Health) pipeline landscape.

Polycystic ovary syndrome (PCOS) is a common hormonal disorder among women of reproductive age. Symptoms include menstrual abnormality, acne, thinning hair on the scalp, weight gain, excess androgen and polycystic ovaries. The main risk factor for polycystic ovary syndrome (PCOS) is a family history. Other factors include type 2 diabetes and heart disease. Treatment includes hormone therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Polycystic Ovarian Syndrome - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Polycystic Ovarian Syndrome (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Polycystic Ovarian Syndrome (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Polycystic Ovarian Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 4, 1, 1, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Polycystic Ovarian Syndrome (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Polycystic Ovarian Syndrome (Women's Health).

- The pipeline guide reviews pipeline therapeutics for Polycystic Ovarian Syndrome (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Polycystic Ovarian Syndrome (Women's Health) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Polycystic Ovarian Syndrome (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Polycystic Ovarian Syndrome (Women's Health)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Polycystic Ovarian Syndrome (Women's Health).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Polycystic Ovarian Syndrome (Women's Health) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Polycystic Ovarian Syndrome - Pipeline Review, H2 2017

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Polycystic Ovarian Syndrome - Overview
Polycystic Ovarian Syndrome - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Polycystic Ovarian Syndrome - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Polycystic Ovarian Syndrome - Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
Bayer AG
Crinetics Pharmaceuticals Inc
EffRx Pharmaceuticals SA
Millendo Therapeutics Inc
Novartis AG
Ogeda SA
Vicore Pharma AB
Polycystic Ovarian Syndrome - Drug Profiles
BAY-1161116 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C-21 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Inhibit Interferon Gamma for Metabolic Disorders and Women's Health - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fezolinetant - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JDSCR-004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KDT-501 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LIK-066 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
metformin hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MLE-4901 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein for Endometriosis, Ovarian Hyperstimulation Syndrome and Polycystic Ovarian Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize FSH Receptor and LH Receptor for Women's Health - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit KISS-1R for Polycystic Ovarian Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Polycystic Ovarian Syndrome - Dormant Projects
Polycystic Ovarian Syndrome - Discontinued Products
Polycystic Ovarian Syndrome - Product Development Milestones
Featured News & Press Releases
Mar 23, 2017: Millendo Therapeutics Announces Data Presentations for MLE4901 at ENDO 2017 and Kisspeptin 2017
Dec 20, 2016: Ogeda announces fezolinetant as INN and issuance of U.S. patent for ESN364
Nov 03, 2016: Millendo Therapeutics Announces Data Presentations at Androgen Excess and Polycystic Ovary Syndrome Society Annual Meeting
Nov 02, 2016: Millendo Therapeutics to present data on MLE-4901 program at Society for Endocrinology British Endocrine Societies Conference
Aug 16, 2016: Millendo Therapeutics Announces Initiation of Phase 2b Clinical Trial of MLE4901 in Patients with Polycystic Ovary Syndrome
Jul 27, 2016: Millendo Therapeutics Announces Publication of Positive Phase 2a Data for MLE4901 for the Treatment of Polycystic Ovary Syndrome
Jul 19, 2016: EUROSCREEN opens US-IND for ESN364 on three Phase II trials
Apr 21, 2015: Euroscreen starts in parallel two Phase 2 clinical trials with ESN364 in UF and PCOS patients
Dec 08, 2014: Euroscreen Announces Positive Completion of Phase I Trial of ESN364
Jun 20, 2014: Euroscreen ESN364 drug candidate presented at the ICE/ENDO Meeting
Jun 10, 2014: EffRx Receives U.S. Orphan Drug Designation for EX404 for Treatment of Pediatric Polycystic Ovary Syndrome
Dec 18, 2013: Euroscreen Initiates Phase I Clinical Trial For ESN364
Oct 01, 2013: EffRx Receives Prestigious EUR 5.9 Million FP7 Research Grant for the Development of EX404 for Polycystic Ovary Syndrome in Pediatric Populations
Feb 05, 2013: Euroscreen to present ESN364 drug candidate at the 11th International Symposium on GnRH
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Polycystic Ovarian Syndrome, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Polycystic Ovarian Syndrome - Pipeline by Addex Therapeutics Ltd, H2 2017
Polycystic Ovarian Syndrome - Pipeline by Bayer AG, H2 2017
Polycystic Ovarian Syndrome - Pipeline by Crinetics Pharmaceuticals Inc, H2 2017
Polycystic Ovarian Syndrome - Pipeline by EffRx Pharmaceuticals SA, H2 2017
Polycystic Ovarian Syndrome - Pipeline by Millendo Therapeutics Inc, H2 2017
Polycystic Ovarian Syndrome - Pipeline by Novartis AG, H2 2017
Polycystic Ovarian Syndrome - Pipeline by Ogeda SA, H2 2017
Polycystic Ovarian Syndrome - Pipeline by Vicore Pharma AB, H2 2017
Polycystic Ovarian Syndrome - Dormant Projects, H2 2017
Polycystic Ovarian Syndrome - Discontinued Products, H2 2017

List of Figures
Number of Products under Development for Polycystic Ovarian Syndrome, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
  • Pharmaceuticals for Women's Health: Global Markets to 2023
    Published: 03-Jul-2018        Price: US 5500 Onwards        Pages: 141
    Report Scope While women's health encompasses several health issues, this report will focus on menopause-related disorders, postmenopausal osteoporosis, endometriosis, polycystic ovarian syndrome and pregnancy disorders. This report does not focus on drugs for infertility, diagnostic and drug technologies for breast cancer or therapies and diagnostics for ovarian cancer. However, we have individuals reports which discusses the scope of these health concerns in detail. The report cod......
  • Menopausal Disorders Drug Development Pipeline Review, 2018
    Published: 29-Jun-2018        Price: US 3995 Onwards        Pages: 84
    Menopausal Disorders Drug Development Pipeline Review, 2018 Summary This report provides an overview of the pipeline landscape for menopausal disorders. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for postmenopausal osteoporosis, vaginal atrophy and vasomotor symptoms of menopause, and features dormant and discontinued products. Postmenopausal osteoporosis is the most common......
  • Global Bacterial Vaginosis Drug Market Research Report 2018
    Published: 29-Jun-2018        Price: US 2900 Onwards        Pages: 109
    This report studies the global Bacterial Vaginosis Drug market status and forecast, categorizes the global Bacterial Vaginosis Drug market size (value & volume) by key players, type, application, and region. This report focuses on the top players in North America, Europe, Asia-Pacific, South America, and Middle East & Africa. The global Bacterial Vaginosis Drug market is valued at million US$ in 2017 and will reach million US$ by the end of 2025, growing at a CAGR of during 201......
  • Global and China Drugs for Vulvovaginal Candidiasis Market Research by Company, Type & Application 2013-2025
    Published: 15-Jun-2018        Price: US 2000 Onwards        Pages: 81
    Summary Market Segment as follows: By Type - Miconazole - Clotrimazole - Fluconazole - Econazole - Other By Application - Hospital & Clinic - Pharmacy By Company - Bayer - Perrigo - J & J - Pfizer - Bristol-Myers Squibb - Effik - Teva - Sanofi - Cisen Pharmaceutical - Kingyork Group The main contents of the repo......
  • Global Assisted Reproductive Technology Market Size, Status and Forecast 2025
    Published: 01-Jun-2018        Price: US 3300 Onwards        Pages: 95
    This report studies the global Assisted Reproductive Technology market, analyzes and researches the Assisted Reproductive Technology development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like - Merck KGaA - CooperSurgical, Inc. - Vitrolife AB. - Hamilton Thorne, Inc. - Nikon Corporation - Nidacon International AB - Laboratoire CCD - Planer PLC......
  • Polycystic Ovarian Syndrome Global Clinical Trials Review, H1, 2018
    Published: 28-May-2018        Price: US 2500 Onwards        Pages: 426
    Polycystic Ovarian Syndrome Global Clinical Trials Review, H1, 2018 Summary GlobalData's clinical trial report, "Polycystic Ovarian Syndrome Global Clinical Trials Review, H1, 2018" provides an overview of Polycystic Ovarian Syndrome clinical trials scenario. This report provides top line data relating to the clinical trials on Polycystic Ovarian Syndrome. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the glo......
  • Global Oral Contraceptive Market Professional Survey Report 2018
    Published: 28-May-2018        Price: US 3500 Onwards        Pages: 103
    This report studies the global Oral Contraceptive market status and forecast, categorizes the global Oral Contraceptive market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, India, Southeast Asia and other regions (Central & South America, and Middle East & Africa). The global Oral Contraceptive market is valued at xx million US$ in 2017 and is expected to reach xx million ......
  • Dysmenorrhea Global Clinical Trials Review, H1, 2018
    Published: 18-May-2018        Price: US 2500 Onwards        Pages: 195
    Dysmenorrhea Global Clinical Trials Review, H1, 2018 Summary GlobalData's clinical trial report, "Dysmenorrhea Global Clinical Trials Review, H1, 2018" provides an overview of Dysmenorrhea clinical trials scenario. This report provides top line data relating to the clinical trials on Dysmenorrhea. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by......
  • Male Hypogonadism Global Clinical Trials Review, H1, 2018
    Published: 18-May-2018        Price: US 2500 Onwards        Pages: 228
    Male Hypogonadism Global Clinical Trials Review, H1, 2018 Summary GlobalData's clinical trial report, "Male Hypogonadism Global Clinical Trials Review, H1, 2018" provides an overview of Male Hypogonadism clinical trials scenario. This report provides top line data relating to the clinical trials on Male Hypogonadism. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of diseas......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs